Shares of Ligand Pharmaceuticals (LGND) are up 135% in 2013. Despite this historic rise, the royalty collecting pharmaceutical company has plenty of room to run as it sees more drug approvals and returns cash to shareholders.
From the company's website:
"Ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. We operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders."
New Approval With Pfizer for Menopause